Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
238 results about "Glycoconjugate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Glycoconjugates is the general classification for carbohydrates covalently linked with other chemical species such as proteins, peptides, lipids and saccharides. Glycoconjugates are formed in processes termed glycosylation.
Methods and products related to the improved analysis of carbohydrates
The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins and saccharides attached to lipids. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information from the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation/altered glycosylation. Such methods are also provided. Methods are further provided to assess production processes, to assess the purity of samples containing glycoconjugates, and to select glycoconjugates with the desired glycosylation.
Owner:MASSACHUSETTS INST OF TECH +2
Glycoconjugates of RNA Interference Agents
ActiveUS20090203135A1Inhibit expression of target geneInhibit expressionOrganic active ingredientsSugar derivativesGlycoconjugateCancer research
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Owner:ALNYLAM PHARM INC
O-linked glycosylation of peptides
The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.
Owner:NOVO NORDISK AS
Novel multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
InactiveUS20010048929A1Inhibition effectWeight increaseAntibacterial agentsPeptide/protein ingredientsSerotypeTumor antigen
Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbohydrate fragments each linker to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inputs enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae, which may be serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F, or Neisseria meningitidis, which may be serotype A, B, C, W-135 or Y. Such oligosaccharide fragments may be sized from 2 to 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule. The multivalent molecules may be employed in vaccines or in the generation of antibodies for diagnostic application.
Owner:CONNAUGHT LAB
Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
InactiveUS20080300173A1Improve blood sugar controlControlled more and lessSugar derivativesBacteriaMammalWild type
The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.
![Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]](https://images-eureka.patsnap.com/patent_img/4ee91e84-dc70-492d-8101-8e27c2003d31/US20080300173A1-20081204-D00001.png "Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]")
![Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]](https://images-eureka.patsnap.com/patent_img/4ee91e84-dc70-492d-8101-8e27c2003d31/US20080300173A1-20081204-C00001.png "Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]")
![Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]](https://images-eureka.patsnap.com/patent_img/4ee91e84-dc70-492d-8101-8e27c2003d31/US20080300173A1-20081204-C00002.png "Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]")
Owner:NOVO NORDISK AS
O-linked glycosylation of peptides
The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.
Owner:NOVO NORDISK AS
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
ActiveUS20150202309A1Excellent characteristicsHigh yieldAntibacterial agentsMedical devicesStreptococcus pneumoniaeVaccination
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Owner:PFIZER INC
Glycoconjugates of RNA interference agents
The present invention relates to agents, compositions and methods for inhibiting the expression of a target gene, comprising an RNAi agent bearing at least one galactosyl moiety. These are useful for delivering the gene expression inhibiting activity to cells, particularly hepatocytes, and more particularly in therapeutic applications.
Owner:ALNYLAM PHARMA INC
Infant Formula
InactiveUS20080125346A1Good effectIncreased proliferationAntibacterial agentsOrganic active ingredientsGlycanPolyphosphate
The present invention relates to a nutritional composition containing protein, fat and carbohydrate; and a. a nucleotide component selected from the group consisting of nucleic acid, nucleic acid derivatives, nucleotides, nucleoside polyphosphates, polynucleotides, nucleosides, ribose, desoxyribose, and dinucleosidpolyphosphates (NpxN); and b. a non-proteinaceous negatively charged, glycan or glycoconjugate component with a molecular weight between 200 and 20.000 dalton. The present nutritional composition is particularly suited for feeding infants as it mimics the protective effects of human milk, in particular against allergies and infections.
Owner:NUTRICIA
Conjugated polysaccharide fabric detergent and conditioning products
InactiveUS6225462B1Advantage of extraExtra compatibilityOrganic detergent compounding agentsSugar derivativesCellulose bindingLocust bean gum
A polysaccharide conjugate comprises a polysaccharide with an attached entity having a molecular weight of at least 5000, the polysaccharide conjugate being capable of binding to cellulose. Preferred polysaccharides include tamarind seed xyloglucan, locust bean gum and enzyme modified guar. The attached entity is suitably a protein such as an enzyme, antibody or antibody fragment, or a particle possibly having a benefit agent such as a fragrance associated therewith. Because the polysaccharide conjugate binds to cellulose, which is present in cotton and other fabrics, paper, etc., binding of the conjugate to cellulose brings the attached entity into close proximity to a surface of or containing cellulose. The invention thus enables targeting of attached entities to such surfaces. The invention also provides a product incorporating the polysaccharide conjugate of the invention. The product is conveniently a laundry product such as a fabric washing product, e.g. a detergent product, or a fabric conditioning product. In this case the attached entity may be an enzyme, a particle bearing fragrance, etc. The invention also provides a method of targeting binding of an entity to cellulose by use of the polysaccharide conjugate of the invention.
Owner:LEVER BROTHERS
Glycoconjugates and methods
Methods for making the functionalized glycoconjugates include (a) contacting a cell with a first monosaccharide, and (b) incubating the cell under conditions whereby the cell (i) internalizes the first monosaccharide, (ii) biochemically processes the first monosaccharide into a second saccharide, (iii) conjugates the saccharide to a carrier to form a glycoconjugate, and (iv) extracellularly expresses the glycoconjugate to form an extracellular glycoconjugate comprising a selectively reactive functional group. Methods for forming products at a cell further comprise contacting the functional group of the extracellularly expressed glycoconjugate with an agent which selectively reacts with the functional group to form a product. Subject compositions include cyto-compatible monosaccharides comprising a nitrogen or ether linked functional group selectively reactive at a cell surface and compositions and cells comprising such saccharides.
Owner:RGT UNIV OF CALIFORNIA
Vaccine
The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and / or IPD.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Imine-forming polysaccharide adjuvants and immunostimulants
InactiveUS7196073B2Improve acceleration performanceEnhance immune responseOrganic active ingredientsBiocideAdjuvantReceptor
The present invention relates to polysaccharide conjugates that comprise: a polysaccharide that binds to surface-receptors present on Antigen Presenting Cells, conjugated to one or more compounds having stable carbonyl groups covalently attached, either directly or via a bifunctional linker. The conjugates are useful as immuno-stimulants and adjuvants.
Owner:GALENICA PHARMA
Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
InactiveUS20130059780A1Controlled more and lessImprove blood sugar controlFungiBacteriaWild typeGlucagon-like peptide-1
The present invention provides polypeptides that include an O-linked glycoconjugate in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. The polypeptides of the invention include wild-type peptides and mutant peptides that include an O-linked glycosylation site that is not present in the wild-type peptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.![Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]](https://images-eureka.patsnap.com/patent_img/9633ebd4-315e-420d-b033-e313e2785e9a/US20130059780A1-20130307-D00001.png "Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]")
![Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]](https://images-eureka.patsnap.com/patent_img/9633ebd4-315e-420d-b033-e313e2785e9a/US20130059780A1-20130307-C00001.png "Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]")
![Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]](https://images-eureka.patsnap.com/patent_img/9633ebd4-315e-420d-b033-e313e2785e9a/US20130059780A1-20130307-C00002.png "Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]")
Owner:NOVO NORDISK AS
Enzymatic modification of glycopeptides
InactiveUS20090292110A1Lower potential for exposureImprove homogeneityPeptide/protein ingredientsPeptide preparation methodsAcyl residueGlycopeptide
The present invention provides glycoconjugates that are formed through the enzymatically-mediated coupling of a glycosyl moiety, e.g., on a peptide or lipid, and a modifying group that includes an acyl group. The conjugates include the modifying group tethered to the glycosyl moiety through a linking moiety that includes an acyl residue. Also provided are methods for preparing the conjugates of the invention
Owner:RATIOPHARM GMBH
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ActiveUS9492559B2Antibacterial agentsBacterial antigen ingredientsStreptococcus pneumoniae conjugatedPrevnar 13
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and / or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Owner:PFIZER INC
Multi oligosaccharide glycoconjugate bacterial meningitis vaccines
InactiveUS6656472B1Inhibition effectWeight increaseAntibacterial agentsAntipyreticSerotypeTumor antigen
Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae which may be serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F), or Neisseria meningitidis, which may be serotype (A, B, C) W-135 or Y. Such oligosaccharide fragments may be sized from about 2 to about 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, Le<Y >or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule. The multivalent molecules may be employed in vaccines or in the generation of antibodies for diagnostic applications.
Owner:AVENTIS PASTEUR LTD
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ActiveUS7960139B2Increased toxicitySugar derivativesMicrobiological testing/measurementFluorescenceWestern blot
The present disclosure relates to a method for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates. The disclosed method incorporates alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars into a cellular glycoconjugate. A chemical probe comprising an azide group and a visual probe or a fluorogenic probe is used to label the alkyne-derivatized sugar-tagged glycoconjugate. In one aspect, the chemical probe binds covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and is visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA or confocal microscopy, and mass spectrometry.
Owner:ACAD SINIC
Glycoconjugation processes and compositions
ActiveUS9517274B2Stable thioether and amide bondReduce severityAntibacterial agentsBacterial antigen ingredientsCarbamateCarrier protein
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Owner:PFIZER INC
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
ActiveUS20080268468A1Increased toxicitySugar derivativesMicrobiological testing/measurementFluorescenceCycloaddition
The present disclosure relates to a method for metabolic oligosaccharide engineering that incorporates derivatized alkyne-bearing sugar analogs as “tags” into cellular glycoconjugates. The disclosed method incorporates alkynyl derivatized Fuc and alkynyl derivatized ManNAc sugars into a cellular glycoconjugate. A chemical probe comprising an azide group and a visual probe or a fluorogenic probe is used to label the alkyne-derivatized sugar-tagged glycoconjugate. In one aspect, the chemical probe binds covalently to the alkynyl group by Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition and is visualized at the cell surface, intracellularly, or in a cellular extract. The labeled glycoconjugate is capable of detection by flow cytometry, SDS-PAGE, Western blot, ELISA or confocal microscopy, and mass spectrometry.
Owner:ACAD SINIC
Novel glycan conjugates and use thereof
ActiveUS20170275389A1Shrink tumorElimination of malignant cellBiological material analysisDepsipeptidesAdjuvantMedicine
This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.
Owner:ACAD SINIC
Enzymatic modification of glycopeptides
InactiveUS20110318780A1Improve homogeneityHigh degree of homogeneityFermentationLipid formationGlycopeptide
The present invention provides glycoconjugates that are formed through the enzymatically-mediated coupling of a glycosyl moiety, e.g., on a peptide or lipid, and a modifying group that includes an acyl group. The conjugates include the modifying group tethered to the glycosyl moiety through a linking moiety that includes an acyl residue. Also provided are methods for preparing the conjugates of the invention
Owner:RATIOPHARM GMBH
Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
ActiveUS20180099039A1Excellent characteristicsHigh yieldPowder deliveryBacterial antigen ingredientsStreptococcus pneumoniaeVaccination
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Owner:PFIZER INC
Glycoconjugate vaccines containing peptidoglycan
InactiveUS20060134141A1Improve efficiencyImproving immunogenicityAntibacterial agentsOrganic active ingredientsMicrobiologyCarrier protein
The present invention relates to vaccines for treating bacterial infections, which vaccines comprise a glycoconjugate immunogen comprising at least one capsular polysaccharide conjugated to a carrier protein, such that the capsular polysaccharide contains an amount of peptidoglycan effective to improve the vaccine's properties.
Owner:NABI BIOPHARMLS
Glycoconjugation processes and compositions
ActiveUS20150216996A1Reduce severityAvoid adjustmentAntibacterial agentsBacterial antigen ingredientsThio-Carrier protein
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Owner:PFIZER INC
Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use
Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds according to FORMULA V and methods of their use,wherein,Ring 1 comprises an aryl or heteroaryl ring having 4 to 8 carbon atoms, among which atoms are counted “X” and “Y”;each of X and Y is optional; X, when present is either —C(R1)2— or —C(R1)2—; Y, when present, is either —CH2— or —CH2—CH2—;z, R5 and R5′ are optional, and when present z, R5 and R5′ together form a lower alkyl or a substituted lower alkyl moiety;N is part of either an amine or an amide linkage;E is a saccharide which forms a linkage with N through a single bond from a carbon or oxygen atom thereof;R1 and R4 are selected form the group consisting of hydrogen, hydroxyl, halogen, halo-lower alkyl, alkoxyl, alkoxyl-lower alkyl, halo-alkoxy, thioamido, amidosulfonyl, alkoxylcarbonyl, carboxamide, aminocarbonyl, and alkylamino-carbonyl;R2 and R3 are hydroxyl;R5 and R6, when present, are selected from the group consisting of hydrogen, hydroxyl, alkoxyl, carbonyl, alkoxylcarbonyl, aminocarbonyl, alkylamino-carbonyl and dialkylamino-carbonyl; and,R6 and R6′ are selected from the group consisting of hydrogen, hydroxyl, alkoxyl, carboxyl, alkoxylcarbonyl, aminocarbonyl, alkylamino-carbonyl and dialylamino-carbonyl,with the proviso that Ring 1 is capable of binding to any of:a dopaminergic receptor selected from the group consisting of a D1 receptor and a D5 receptor; a DAT transporter; a VMAT transporter; and,with the proviso that E is capable of binding to a GLUT transporter selected from the group consisting of a GLUT1 receptor and a GLUT3 receptor.
Owner:GLYCON
Synthetic peptides, conjugation reagents and methods
InactiveUS20060035305A1Sugar derivativesPeptide/protein ingredientsCrystallographyAmino-Levulinic Acid
The invention provides methods and compositions useful for making synthetic peptide conjugates. In one embodiment, the invention provides compositions comprising the structure: wherein R is selected from lower substituted or unsubstituted alkyl, O, NH and S and P is an amine protection group. In more particular embodiments, the compositions comprise α-amine protected 4,5-dehydroleucine or α-amine protected (2S)-aminolevulinic acid and / or P is F-moc. These compounds may be incorporated into peptides, for example, peptides comprising a substituted or unsubstituted (2S)-aminolevulinic acid residue, such as (2S)-aminolevulinic acid residue is substituted with an O- or N-linked glycoconjugate, or a detectable label.
Owner:RGT UNIV OF CALIFORNIA
Methods and products related to the improved analysis of carbohydrates
The invention relates, in part, to the improved analysis of carbohydrates. In particular, the invention relates to the analysis of carbohydrates, such as N-glycans and O-glycans found on proteins and saccharides attached to lipids. Improved methods, therefore, for the study of glycosylation patterns on cells, tissue and body fluids are also provided. Information from the analysis of glycans, such as the glycosylation patterns on cells, tissues and in body fluids, can be used in diagnostic and treatment methods as well as for facilitating the study of the effects of glycosylation / altered glycosylation. Such methods are also provided. Methods are further provided to assess production processes, to assess the purity of samples containing glycoconjugates, and to select glycoconjugates with the desired glycosylation.
Owner:MOMENTA PHARMA INC +1
Glycoconjugation processes and compositions
ActiveUS20170224804A1Stable thioether and amide bondReduce severityAntibacterial agentsBacterial antigen ingredientsThio-Carrier protein
The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.
Owner:PFIZER INC
Modified polysaccharides for conjugate vaccines
InactiveUS20100189740A1Good antigenicityContribute to the valency of the vaccineAntibacterial agentsDepsipeptidesConjugate vaccineMicroorganism
The present invention relates to methods of manufacture of immunogenic glycoconjugates, in particular for use in pharmaceutical compositions for inducing a therapeutic immune response in a subject. The immunogenic glycoconjugates of the invention comprise one or more oligosaccharides or polysaccharides that are conjugated to one or more carrier proteins via an active aldehyde group. Accordingly, the invention provides methods of making (i) unsaturated microbial N-acyl derivative oligosaccharides or polysaccharides; (ii) novel conjugates of unsaturated N-acyl derivatives; and (iii) glycoconjugate compositions comprising conjugate molecules of fragments of microbial unsaturated N-acyl derivatives that serve as a covalent linker to one or more proteins. The invention further encompasses the use of the immunogenic glycoconjugates pharmaceutical compositions for the prevention or treatment of an infectious disease.
Owner:PFIZER IRELAND PHARM CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap